Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / ADCT - Limiting Concerns On ADC Therapeutics' Prospects

ADCT - Limiting Concerns On ADC Therapeutics' Prospects

ADC Therapeutics SA

2024-06-06 09:02:29 ET

Summary

  • ADC Therapeutics is developing antibody-drug conjugates for hematologic cancers and solid tumors.
  • Their drug Zynlonta shows promise in targeting and killing cancer cells while reducing damage to healthy tissues.
  • ADCT's pipeline includes ADCT-601 and ADCT-602 for solid tumors and acute lymphoblastic leukemia.
  • ADCT has significant cash burn and debt, leading to financial constraints and a limited cash runway.
  • Despite a promising pipeline, ADCT's high valuation and competitive challenges justify a "hold" rating.

For further details see:

Limiting Concerns On ADC Therapeutics' Prospects
Stock Information
Company Name: ADC Therapeutics SA
Stock Symbol: ADCT
Market: NYSE
Website: adctherapeutics.com
Menu
ADCT ADCT Quote ADCT Short ADCT News ADCT Articles ADCT Message Board
Get ADCT Alerts

News, Short Squeeze, Breakout and More Instantly...